PAVmed (PAVM) Set to Announce Earnings on Friday

PAVmed (NASDAQ:PAVM) is expected to be releasing its Q3 2026 results before the market opens on Friday, November 13th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.03 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

PAVmed Stock Performance

PAVM stock opened at $1.60 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.98. PAVmed has a 52 week low of $1.17 and a 52 week high of $28.44. The firm’s fifty day moving average is $3.02 and its 200 day moving average is $6.29.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, PAVmed presently has an average rating of “Hold” and an average price target of $56.00.

About PAVmed

PAVmed Inc. is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care. One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease.